JOUNCE THERAPEUTICS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2013-01-01
- Employees
- 141
- Market Cap
- -
- Website
- http://www.jouncetx.com
Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT04669899
- Locations
- 🇺🇸
Cedars Sinai, Los Angeles, California, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT04549025
- Locations
- 🇺🇦
Kyiv Railway Clinical Hospital #3 of Branch Health Center of the PJSC Ukrainian Railway, Kyiv, Ukraine
🇬🇪Arensia Tbilisi - PPDS, Tbilisi, Georgia
🇭🇺Veszprem Megyei Tudogyogyintezet, Farkasgyepű, Hungary
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT04319224
- Locations
- 🇺🇸
The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Virginia Health Systems, Charlottesville, Virginia, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT03989362
- Locations
- 🇺🇸
University of Southern California Medical Center, Los Angeles, California, United States
🇺🇸University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Allegheny Health Network Research Institute, Pittsburgh, Pennsylvania, United States
Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03790488
- Locations
- 🇺🇸
START Midwest - Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT02904226
- Locations
- 🇺🇸
The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States